Posted by Michael Wonder on 17 Sep 2016
ICER announces updates to timeline for review of therapies for multiple sclerosis
16 September 2016 - The ICER has updated the timeline of its review of disease-modifying therapies for patients with multiple sclerosis.
As part of ICER's commitment to ensuring that all perspectives are heard in the development of its reports, the agency has expanded the public comment period for the Draft Evidence Report, set to be released on November 22, 2016. Previously scheduled for three weeks, the public comment period will now run for four weeks to allow added time for stakeholder input.
Based on the extension, the updated Evidence Report will be posted on or about January 26, 2017. This Evidence Report will form the basis for discussion at the February 2017 meeting of the California Technology Assessment Forum.
